Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

HER2-positive breast cancers have poorer prognosis and are prime candidates for molecular-targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction. While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Andrea L. A., Lee, Soo-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357513/
https://www.ncbi.nlm.nih.gov/pubmed/22649737
http://dx.doi.org/10.1155/2012/415170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357513/
https://www.ncbi.nlm.nih.gov/pubmed/22649737
http://dx.doi.org/10.1155/2012/415170

Ejemplares similares